Crown Bioscience, a JSR Life Sciences company, has opened a new oncology-focused research facility in Zhongshan, China to satisfy increased customer demand.
 
Once completed, this new building will add more than 2,000m² of new vivarium space to support CrownBio’s in vivo oncology platforms, helping satisfy predicted near-term growth.
 
CrownBio’s products and services are used by pharmaceutical and biotech customers across APAC, North America, and Europe to accelerate and de-risk their drug discovery programs. With the significant and continued growth of CrownBio’s client base, the Zhongshan facility has been purpose-built to meet expanding study needs.
 
The research and drug development facility features BSL-2 laboratories and will include an ABSL-2 vivarium. Initial capabilities will focus on expanding cell line-derived xenograft model availability and study throughput, with an increased roster of cutting edge, translational oncology models becoming available. Full operational capacity is expected in early 2021.
 
“The establishment of our new Zhongshan facility demonstrates our continued commitment to our clients, to provide sustained rapid study initiation combined with robust cost-effectiveness,” said John Gu, chief operating officer at CrownBio. “Through our growth, we can more fully support our clients in their goals of more rapid and efficient cancer drug development.”
 
A site opening event and ribbon cutting ceremony took place on October 30, 2020.